Estrogen receptor and endothelial dysfunction

Autores
Valle, María Ivone; Rauschemberger, María Belén; Espeche, Walter; Salazar, M.; Plunkett, Ricardo; Massheimer, Virginia Laura
Año de publicación
2019
Idioma
español castellano
Tipo de recurso
documento de conferencia
Estado
versión publicada
Descripción
Estrogen receptor (ER) plays key role on vascular homeostasis. Alterations of ER signaling could conduct to vascular dysfunction, impairment of angiogenesis and platelet aggregation and activation. Preeclampsia (PE) is a pregnancy disease that exhibits these features. We have previously reported that the ER activation by estrone (E1), second natural estrogen, stimulates vasodilators synthesis (NO and PGI2) and inhibits platelet aggregation. This work presents basic (1) and clinical (2) results about the association of ER and vascular dysfunction. 1) Endothelial cells (EC) were incubated with E1 10 nM for 24 h. (2) We tested the existence of association between polymorphisms of ESR1 with PE in a high-risk pregnant women population. Polymorphic variants were studied by RFLP-PCR, employing PvuII and XbaI and resolved by electrophoresis in agarose gels. The in vitro treatment of EC with E1 shows that the hormone stimulated EC growth (91% a/C, p<0.001) and VEGF synthesis. ICI 182780 (ER antagonist), suppressed E1 action. In pregnancy women, the frequencies determined by PvuII was 29% 1(C/T); 59% 2(T/T) and 12% 3(C/C). When XbaI was used the distribution was 35.3% A(A/G); 2% B(A/A) and 62.7% C(G/G). The main haplotype determined was 2C. In contrast, in young women without PE risk the main was 1A.When plasmatic levels of NO were measured, PE pregnant women exhibits a significant reduction in the vasoactive production respect to the whole pregnant population (0.150.024 vs 0.290.040 mM NO/plasma resp.) Results shows that E1 and ER have relevant action on cellular processes involved in endothelial dysfunction. Since the distribution of RE genotypes is different among young women with and without risk of endothelial dysfunction, it could suggest a possible clinical utility of these markers as PE risk predictors.
Fil: Valle, María Ivone. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Bahía Blanca. Instituto de Ciencias Biológicas y Biomédicas del Sur. Universidad Nacional del Sur. Departamento de Biología, Bioquímica y Farmacia. Instituto de Ciencias Biológicas y Biomédicas del Sur; Argentina
Fil: Rauschemberger, María Belén. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Bahía Blanca. Instituto de Ciencias Biológicas y Biomédicas del Sur. Universidad Nacional del Sur. Departamento de Biología, Bioquímica y Farmacia. Instituto de Ciencias Biológicas y Biomédicas del Sur; Argentina
Fil: Espeche, Walter. Provincia de Buenos Aires. Hospital Interzonal General de Agudos Gral. San Martín; Argentina
Fil: Salazar, M.. Provincia de Buenos Aires. Hospital Interzonal General de Agudos Gral. San Martín; Argentina
Fil: Plunkett, Ricardo. Hospital Privado Dr. Raúl Matera. Servicio de Endocrinología; Argentina
Fil: Massheimer, Virginia Laura. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Bahía Blanca. Instituto de Ciencias Biológicas y Biomédicas del Sur. Universidad Nacional del Sur. Departamento de Biología, Bioquímica y Farmacia. Instituto de Ciencias Biológicas y Biomédicas del Sur; Argentina
LXIV Reunión Anual de la Sociedad Argentina de Investigación Clínica (SAIC); LI Reunión Anual de la Asociación Argentina de Farmacología Experimental (SAFE); XXI Reunión Anual de la Sociedad Argentina de Biología (SAB); XXXI Reunión Anual de la Sociedad Argentina de Protozoología (SAP) y IX Reunión Anual de la Asociación Argentina de Nanomedicinas (NANOMED-ar)
Mar del Plata
Argentina
Sociedad Argentina de Investigación Clínica
Asociación Argentina de Farmacología Experimenta
Sociedad Argentina de Biología
Sociedad Argentina de Protozoología
Asociación Argentina de Nanomedicinas
Materia
POLIMORFISMOS
RECEPTOR DE ESTROGENOS
SALUD VASCULAR
PRE-ECLAMPSIA
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/156516
Acceder
id CONICETDig_6c77d2432f1772bcd5f08e68e747827f
oai_identifier_str oai:ri.conicet.gov.ar:11336/156516
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Estrogen receptor and endothelial dysfunctionValle, María IvoneRauschemberger, María BelénEspeche, WalterSalazar, M.Plunkett, RicardoMassheimer, Virginia LauraPOLIMORFISMOSRECEPTOR DE ESTROGENOSSALUD VASCULARPRE-ECLAMPSIAhttps://purl.org/becyt/ford/3.1https://purl.org/becyt/ford/3Estrogen receptor (ER) plays key role on vascular homeostasis. Alterations of ER signaling could conduct to vascular dysfunction, impairment of angiogenesis and platelet aggregation and activation. Preeclampsia (PE) is a pregnancy disease that exhibits these features. We have previously reported that the ER activation by estrone (E1), second natural estrogen, stimulates vasodilators synthesis (NO and PGI2) and inhibits platelet aggregation. This work presents basic (1) and clinical (2) results about the association of ER and vascular dysfunction. 1) Endothelial cells (EC) were incubated with E1 10 nM for 24 h. (2) We tested the existence of association between polymorphisms of ESR1 with PE in a high-risk pregnant women population. Polymorphic variants were studied by RFLP-PCR, employing PvuII and XbaI and resolved by electrophoresis in agarose gels. The in vitro treatment of EC with E1 shows that the hormone stimulated EC growth (91% a/C, p<0.001) and VEGF synthesis. ICI 182780 (ER antagonist), suppressed E1 action. In pregnancy women, the frequencies determined by PvuII was 29% 1(C/T); 59% 2(T/T) and 12% 3(C/C). When XbaI was used the distribution was 35.3% A(A/G); 2% B(A/A) and 62.7% C(G/G). The main haplotype determined was 2C. In contrast, in young women without PE risk the main was 1A.When plasmatic levels of NO were measured, PE pregnant women exhibits a significant reduction in the vasoactive production respect to the whole pregnant population (0.150.024 vs 0.290.040 mM NO/plasma resp.) Results shows that E1 and ER have relevant action on cellular processes involved in endothelial dysfunction. Since the distribution of RE genotypes is different among young women with and without risk of endothelial dysfunction, it could suggest a possible clinical utility of these markers as PE risk predictors.Fil: Valle, María Ivone. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Bahía Blanca. Instituto de Ciencias Biológicas y Biomédicas del Sur. Universidad Nacional del Sur. Departamento de Biología, Bioquímica y Farmacia. Instituto de Ciencias Biológicas y Biomédicas del Sur; ArgentinaFil: Rauschemberger, María Belén. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Bahía Blanca. Instituto de Ciencias Biológicas y Biomédicas del Sur. Universidad Nacional del Sur. Departamento de Biología, Bioquímica y Farmacia. Instituto de Ciencias Biológicas y Biomédicas del Sur; ArgentinaFil: Espeche, Walter. Provincia de Buenos Aires. Hospital Interzonal General de Agudos Gral. San Martín; ArgentinaFil: Salazar, M.. Provincia de Buenos Aires. Hospital Interzonal General de Agudos Gral. San Martín; ArgentinaFil: Plunkett, Ricardo. Hospital Privado Dr. Raúl Matera. Servicio de Endocrinología; ArgentinaFil: Massheimer, Virginia Laura. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Bahía Blanca. Instituto de Ciencias Biológicas y Biomédicas del Sur. Universidad Nacional del Sur. Departamento de Biología, Bioquímica y Farmacia. Instituto de Ciencias Biológicas y Biomédicas del Sur; ArgentinaLXIV Reunión Anual de la Sociedad Argentina de Investigación Clínica (SAIC); LI Reunión Anual de la Asociación Argentina de Farmacología Experimental (SAFE); XXI Reunión Anual de la Sociedad Argentina de Biología (SAB); XXXI Reunión Anual de la Sociedad Argentina de Protozoología (SAP) y IX Reunión Anual de la Asociación Argentina de Nanomedicinas (NANOMED-ar)Mar del PlataArgentinaSociedad Argentina de Investigación ClínicaAsociación Argentina de Farmacología ExperimentaSociedad Argentina de BiologíaSociedad Argentina de ProtozoologíaAsociación Argentina de NanomedicinasFundacion Revista Medicina2019info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/conferenceObjectReuniónJournalhttp://purl.org/coar/resource_type/c_5794info:ar-repo/semantics/documentoDeConferenciaapplication/pdfapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/156516Estrogen receptor and endothelial dysfunction; LXIV Reunión Anual de la Sociedad Argentina de Investigación Clínica (SAIC); LI Reunión Anual de la Asociación Argentina de Farmacología Experimental (SAFE); XXI Reunión Anual de la Sociedad Argentina de Biología (SAB); XXXI Reunión Anual de la Sociedad Argentina de Protozoología (SAP) y IX Reunión Anual de la Asociación Argentina de Nanomedicinas (NANOMED-ar); Mar del Plata; Argentina; 2019; 1-80025-76801669-9106CONICET DigitalCONICETspainfo:eu-repo/semantics/altIdentifier/url/https://www.medicinabuenosaires.cominfo:eu-repo/semantics/altIdentifier/url/https://medicinabuenosaires.com/revistas/vol79-19/s4/vol79_s4.pdfNacionalinfo:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-10-15T15:28:06Zoai:ri.conicet.gov.ar:11336/156516instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-10-15 15:28:06.356CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Estrogen receptor and endothelial dysfunction
title Estrogen receptor and endothelial dysfunction
spellingShingle Estrogen receptor and endothelial dysfunction
Valle, María Ivone
POLIMORFISMOS
RECEPTOR DE ESTROGENOS
SALUD VASCULAR
PRE-ECLAMPSIA
title_short Estrogen receptor and endothelial dysfunction
title_full Estrogen receptor and endothelial dysfunction
title_fullStr Estrogen receptor and endothelial dysfunction
title_full_unstemmed Estrogen receptor and endothelial dysfunction
title_sort Estrogen receptor and endothelial dysfunction
dc.creator.none.fl_str_mv Valle, María Ivone
Rauschemberger, María Belén
Espeche, Walter
Salazar, M.
Plunkett, Ricardo
Massheimer, Virginia Laura
author Valle, María Ivone
author_facet Valle, María Ivone
Rauschemberger, María Belén
Espeche, Walter
Salazar, M.
Plunkett, Ricardo
Massheimer, Virginia Laura
author_role author
author2 Rauschemberger, María Belén
Espeche, Walter
Salazar, M.
Plunkett, Ricardo
Massheimer, Virginia Laura
author2_role author
author
author
author
author
dc.subject.none.fl_str_mv POLIMORFISMOS
RECEPTOR DE ESTROGENOS
SALUD VASCULAR
PRE-ECLAMPSIA
topic POLIMORFISMOS
RECEPTOR DE ESTROGENOS
SALUD VASCULAR
PRE-ECLAMPSIA
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.1
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv Estrogen receptor (ER) plays key role on vascular homeostasis. Alterations of ER signaling could conduct to vascular dysfunction, impairment of angiogenesis and platelet aggregation and activation. Preeclampsia (PE) is a pregnancy disease that exhibits these features. We have previously reported that the ER activation by estrone (E1), second natural estrogen, stimulates vasodilators synthesis (NO and PGI2) and inhibits platelet aggregation. This work presents basic (1) and clinical (2) results about the association of ER and vascular dysfunction. 1) Endothelial cells (EC) were incubated with E1 10 nM for 24 h. (2) We tested the existence of association between polymorphisms of ESR1 with PE in a high-risk pregnant women population. Polymorphic variants were studied by RFLP-PCR, employing PvuII and XbaI and resolved by electrophoresis in agarose gels. The in vitro treatment of EC with E1 shows that the hormone stimulated EC growth (91% a/C, p<0.001) and VEGF synthesis. ICI 182780 (ER antagonist), suppressed E1 action. In pregnancy women, the frequencies determined by PvuII was 29% 1(C/T); 59% 2(T/T) and 12% 3(C/C). When XbaI was used the distribution was 35.3% A(A/G); 2% B(A/A) and 62.7% C(G/G). The main haplotype determined was 2C. In contrast, in young women without PE risk the main was 1A.When plasmatic levels of NO were measured, PE pregnant women exhibits a significant reduction in the vasoactive production respect to the whole pregnant population (0.150.024 vs 0.290.040 mM NO/plasma resp.) Results shows that E1 and ER have relevant action on cellular processes involved in endothelial dysfunction. Since the distribution of RE genotypes is different among young women with and without risk of endothelial dysfunction, it could suggest a possible clinical utility of these markers as PE risk predictors.
Fil: Valle, María Ivone. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Bahía Blanca. Instituto de Ciencias Biológicas y Biomédicas del Sur. Universidad Nacional del Sur. Departamento de Biología, Bioquímica y Farmacia. Instituto de Ciencias Biológicas y Biomédicas del Sur; Argentina
Fil: Rauschemberger, María Belén. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Bahía Blanca. Instituto de Ciencias Biológicas y Biomédicas del Sur. Universidad Nacional del Sur. Departamento de Biología, Bioquímica y Farmacia. Instituto de Ciencias Biológicas y Biomédicas del Sur; Argentina
Fil: Espeche, Walter. Provincia de Buenos Aires. Hospital Interzonal General de Agudos Gral. San Martín; Argentina
Fil: Salazar, M.. Provincia de Buenos Aires. Hospital Interzonal General de Agudos Gral. San Martín; Argentina
Fil: Plunkett, Ricardo. Hospital Privado Dr. Raúl Matera. Servicio de Endocrinología; Argentina
Fil: Massheimer, Virginia Laura. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Bahía Blanca. Instituto de Ciencias Biológicas y Biomédicas del Sur. Universidad Nacional del Sur. Departamento de Biología, Bioquímica y Farmacia. Instituto de Ciencias Biológicas y Biomédicas del Sur; Argentina
LXIV Reunión Anual de la Sociedad Argentina de Investigación Clínica (SAIC); LI Reunión Anual de la Asociación Argentina de Farmacología Experimental (SAFE); XXI Reunión Anual de la Sociedad Argentina de Biología (SAB); XXXI Reunión Anual de la Sociedad Argentina de Protozoología (SAP) y IX Reunión Anual de la Asociación Argentina de Nanomedicinas (NANOMED-ar)
Mar del Plata
Argentina
Sociedad Argentina de Investigación Clínica
Asociación Argentina de Farmacología Experimenta
Sociedad Argentina de Biología
Sociedad Argentina de Protozoología
Asociación Argentina de Nanomedicinas
description Estrogen receptor (ER) plays key role on vascular homeostasis. Alterations of ER signaling could conduct to vascular dysfunction, impairment of angiogenesis and platelet aggregation and activation. Preeclampsia (PE) is a pregnancy disease that exhibits these features. We have previously reported that the ER activation by estrone (E1), second natural estrogen, stimulates vasodilators synthesis (NO and PGI2) and inhibits platelet aggregation. This work presents basic (1) and clinical (2) results about the association of ER and vascular dysfunction. 1) Endothelial cells (EC) were incubated with E1 10 nM for 24 h. (2) We tested the existence of association between polymorphisms of ESR1 with PE in a high-risk pregnant women population. Polymorphic variants were studied by RFLP-PCR, employing PvuII and XbaI and resolved by electrophoresis in agarose gels. The in vitro treatment of EC with E1 shows that the hormone stimulated EC growth (91% a/C, p<0.001) and VEGF synthesis. ICI 182780 (ER antagonist), suppressed E1 action. In pregnancy women, the frequencies determined by PvuII was 29% 1(C/T); 59% 2(T/T) and 12% 3(C/C). When XbaI was used the distribution was 35.3% A(A/G); 2% B(A/A) and 62.7% C(G/G). The main haplotype determined was 2C. In contrast, in young women without PE risk the main was 1A.When plasmatic levels of NO were measured, PE pregnant women exhibits a significant reduction in the vasoactive production respect to the whole pregnant population (0.150.024 vs 0.290.040 mM NO/plasma resp.) Results shows that E1 and ER have relevant action on cellular processes involved in endothelial dysfunction. Since the distribution of RE genotypes is different among young women with and without risk of endothelial dysfunction, it could suggest a possible clinical utility of these markers as PE risk predictors.
publishDate 2019
dc.date.none.fl_str_mv 2019
dc.type.none.fl_str_mv info:eu-repo/semantics/publishedVersion
info:eu-repo/semantics/conferenceObject
Reunión
Journal
http://purl.org/coar/resource_type/c_5794
info:ar-repo/semantics/documentoDeConferencia
status_str publishedVersion
format conferenceObject
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/156516
Estrogen receptor and endothelial dysfunction; LXIV Reunión Anual de la Sociedad Argentina de Investigación Clínica (SAIC); LI Reunión Anual de la Asociación Argentina de Farmacología Experimental (SAFE); XXI Reunión Anual de la Sociedad Argentina de Biología (SAB); XXXI Reunión Anual de la Sociedad Argentina de Protozoología (SAP) y IX Reunión Anual de la Asociación Argentina de Nanomedicinas (NANOMED-ar); Mar del Plata; Argentina; 2019; 1-8
0025-7680
1669-9106
CONICET Digital
CONICET
url http://hdl.handle.net/11336/156516
identifier_str_mv Estrogen receptor and endothelial dysfunction; LXIV Reunión Anual de la Sociedad Argentina de Investigación Clínica (SAIC); LI Reunión Anual de la Asociación Argentina de Farmacología Experimental (SAFE); XXI Reunión Anual de la Sociedad Argentina de Biología (SAB); XXXI Reunión Anual de la Sociedad Argentina de Protozoología (SAP) y IX Reunión Anual de la Asociación Argentina de Nanomedicinas (NANOMED-ar); Mar del Plata; Argentina; 2019; 1-8
0025-7680
1669-9106
CONICET Digital
CONICET
dc.language.none.fl_str_mv spa
language spa
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/url/https://www.medicinabuenosaires.com
info:eu-repo/semantics/altIdentifier/url/https://medicinabuenosaires.com/revistas/vol79-19/s4/vol79_s4.pdf
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
application/pdf
dc.coverage.none.fl_str_mv Nacional
dc.publisher.none.fl_str_mv Fundacion Revista Medicina
publisher.none.fl_str_mv Fundacion Revista Medicina
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1846083422247714816
score 13.22299

Publicaciones similares